Bolt Biotherapeutics acquires Prana Therapies alongside $120 million financing to advance inflammatory disease pipeline
Bolt Biotherapeutics has acquired Prana Therapies in a stock-for-stock transaction and arranged $120 million in financing to advance a new inflammatory disease pipeline.
The acquisition adds Prana Therapies' INSPIRE multispecific antibody platform and lead candidate PRA-216, an investigational IL-4Rα/TSLP bispecific antibody in Phase II development for asthma, COPD and atopic dermatitis.
Bolt separately arranged a $120 million private placement with the potential for up to $60 million in additional warrant proceeds, providing funding intended to support operations into 2028; these financing amounts are separate from the acquisition consideration.
Field | Content |
Article Type | Deals |
Acquirer | Bolt Biotherapeutics |
Acquired Company | Prana Therapies |
Deal Type | Stock-for-stock acquisition structured as a reverse merger |
Transaction Status | Completed |
Announcement Date | 23 October 2026 |
Acquisition Consideration | Stock-for-stock; monetary valuation not specified in supplied summary |
Acquired Technology Platform | INSPIRE multispecific antibody platform |
Lead Acquired Asset | PRA-216 |
Therapeutic Modality | Bispecific antibody |
Molecular Targets | IL-4Rα and TSLP |
Therapeutic Area | Immunology and inflammatory diseases |
Target Indications | Asthma; chronic obstructive pulmonary disease; atopic dermatitis |
Development Stage | Phase II |
Separate Financing | $120 million private placement |
Potential Additional Financing | Up to $60 million from warrant exercises |
Total Potential Financing | Up to $180 million including contingent warrant proceeds |
Financing Versus Acquisition Consideration | The private placement and potential warrant proceeds are separate financing arrangements and are not acquisition consideration |
Expected Cash Runway | Into 2028, according to the supplied transaction summary |
Financing Purpose | Support clinical development and company operations |
Geography | Not specified in supplied summary |
What Happened | Bolt Biotherapeutics acquired Prana Therapies in a stock-for-stock transaction and separately arranged a $120 million private placement. |
Why It Matters | The acquisition adds a Phase II inflammatory disease candidate and a multispecific antibody platform, repositioning Bolt's development pipeline. |
Strategic Rationale | Combine Prana's investigational immunology assets with Bolt's corporate and development infrastructure, supported by new financing. |
Pipeline Impact | PRA-216 provides exposure to asthma, COPD and atopic dermatitis development programmes. |
Financial Impact | The $120 million private placement and up to $60 million in potential warrant proceeds are intended to extend the company's operating runway into 2028. |
Key Takeaway | Bolt has acquired a clinical-stage inflammatory disease pipeline through a stock transaction, while securing separate financing to support its development strategy. |
What to Watch | PRA-216 Phase II clinical results, subsequent development plans, regulatory interactions, warrant exercises and the company's operating cash runway. |
Primary Source | Bolt Biotherapeutics |
Primary Source URL | https://investors.boltbio.com/news-releases/news-release-details/bolt-biotherapeutics-announces-acquisition-prana-therapies-and |
Relevant Date | 23 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
댓글